台股 » 個股 » 生展 » 籌碼相關 » 券商分點績效 » 券商分點個股進出

生展

(8279)
  • 股價
    158.5
  • 漲跌
    ▼1.5
  • 漲幅
    -0.94%
  • 成交量
    10
  • 產業
    上櫃 生技醫療類股
  • 67人加入追蹤

    立即追蹤

  • 本地時間:13:35(已收盤)

     
生展 (8279)籌碼相關-光和-溪湖 券商分點個股進出
券商分點績效/獲利分析

透過統計各券商分點在長期買賣某個股的操作績效,來找出真正獲利的贏家所在券商分點,進而追蹤此贏家所操作的股票與軌跡。

光和-溪湖 券商分點個股進出

日期買進張數買進均價賣出張數賣出均價收盤價買賣超60日均量成交佔比 大量交易提示
2023/05/3000.000.1186.50186.50-0.161-0.08%
2023/04/190.1184.0000.00183.500.1490.10%
2023/01/1000.000.1157.00154.00-0.168-0.15%
2022/11/170.1147.0000.00149.500.1740.13%
2022/03/2300.002124.50125.50-271-2.80%
2022/03/032120.5000.00121.002712.79%
2021/01/2000.000.1101.00100.50-0.141-0.24%
2020/02/1100.001106.50106.50-167-1.47%
2019/11/281122.0000.00119.501661.51%
2019/10/1500.001126.50126.00-192-1.08%
2019/08/2900.001148.00148.00-1113-0.88%
2019/08/121139.0000.00139.5011020.98%
2019/07/0100.000.1138.50139.50-0.154-0.18%
2019/06/2800.001129.50128.00-149-2.01%
2018/11/1300.00193.1093.30-144-2.26%
2018/10/1100.00285.0085.50-255-3.61%
2018/10/09290.9000.0092.402533.73%
2018/10/0400.002102.00100.50-252-3.82%
2018/10/0300.008100.50100.50-849-16.13%
2018/10/0200.00290.3591.50-249-4.05%
2018/09/2700.001290.0089.80-1252-22.95%
2018/09/18292.0000.0092.502533.77%
2018/09/1700.00492.5593.50-454-7.37%
2018/08/213101.0000.0099.503793.75%
2018/08/201101.0000.00101.001791.26%
2018/08/1700.003103.00103.00-380-3.74%
2018/08/167101.5000.00101.007808.70%
2018/08/1411104.001106.00105.50108112.27%
2018/08/134111.0000.00105.504814.90%
2018/08/104115.0000.00115.504804.98%
2018/06/261142.5000.00141.5012740.36%
2018/04/2700.002152.75158.50-2364-0.55%
2018/04/241164.0000.00161.5013740.27%
2018/04/202170.0000.00173.0023420.58%
2018/04/1200.001158.00158.50-1335-0.30%
2018/04/111158.0000.00158.0013330.30%
2018/03/1500.009140.50144.50-9278-3.23%
2018/03/1300.006135.00134.50-6287-2.09%
2018/03/126133.5000.00133.5062902.06%
2018/03/096133.506135.50136.5002920.00%
2018/03/089137.0000.00137.0092933.07%
2018/02/2100.001128.50130.50-1311-0.32%
2018/01/091172.0000.00172.5012810.36%
〈國光生展望〉子公司安特羅腸病毒三期臨床入尾聲 明年展開IPOAnue鉅亨-2023/12/26
〈國光生展望〉流感疫苗申請巴西藥證+破傷風切新市場 外銷業績拚成長Anue鉅亨-2023/12/26
〈聯合再生展望〉洪傳獻:TOPCon技術明年成主流 獲利表現佳Anue鉅亨-2023/10/16
生展 相關文章